Non-Dilutive Funding
Also known as Non-Dilutive Capital, Non-Dilutive Financing, Equity-Free Funding
Non-dilutive funding is capital that does not require issuing equity in exchange. It includes grants, R&D tax credits, revenue-based financing, customer prepayments, and certain forms of debt where the lender takes no equity beyond minor warrant coverage. The SBIR/STTR program is the largest US source, awarding over $4B per year.
In depth
Non-dilutive funding is a category, not an instrument. It groups every form of capital that does not require the company to issue new equity in exchange. The economics vary widely across the category, but they share one property: existing ownership stays intact when the money arrives.
The largest US source is the SBIR/STTR program, which awards over $4B per year through eleven federal agencies. NSF, DoD, NIH, DARPA, ARPA-E, and DoE all run program offices that fund commercial R&D in their domains. Phase I awards are typically up to roughly $323K, Phase II up to roughly $2.15M, with Phase III being commercialization support rather than direct funding. A deep-tech founder can stack awards across agencies and accumulate several million dollars before raising a priced round.
The other major sources are state-level grants, federal R&D tax credits (the IRC Section 41 credit refunds a percentage of qualifying research spending and can be applied against payroll taxes by qualifying small businesses), revenue-based financing from specialty lenders like Pipe, Capchase, and Lighter Capital, and customer prepayments where a strategic buyer funds product development in exchange for early access. Foundation grants and prize competitions round out the category.
Why it matters
Non-dilutive funding is the cheapest capital on the menu for any company that qualifies. A founder who funds two years of R&D with $3M of SBIR awards plus a $1M R&D tax credit refund has effectively raised a Series A worth of capital without giving up a single share. At a $20M post-money valuation, that is 20% of the company preserved.
The constraint is fit. SBIR/STTR funds R&D, not sales and marketing. Revenue-based financing requires predictable revenue. R&D tax credits require qualifying research expenditure that survives IRS scrutiny. Companies that match their use of funds to the right non-dilutive source can run on it for years; companies that try to fund the wrong activities with the wrong source waste cycles and end up taking equity anyway.
Worked example
A deep-tech hardware startup raises capital across two years using a non-dilutive stack before its Series A:
| Source | Amount | Type | Constraints |
|---|---|---|---|
| NSF SBIR Phase I | $305K | Grant | R&D milestones, 12 months |
| NSF SBIR Phase II | $1.25M | Grant | Phase I completion required, 24 months |
| State innovation grant | $250K | Grant | In-state operations |
| Federal R&D tax credit | $400K | Cash refund vs payroll tax | Qualifying R&D expenditure |
| Strategic customer prepayment | $750K | Revenue | Early product access |
Total non-dilutive raised = $2.96M
Equity sold = $0
Implied dilution avoided = ~$2.96M / $15M target Series A pre ≈ 20%
The founders entered their Series A negotiation owning 20 percentage points more of the company than the same trajectory would have produced via pure equity funding. The math only works because the company's activities were R&D-heavy enough to qualify for the grants and credits in the first place.
Frequently asked
What counts as non-dilutive funding?
Federal and state grants (SBIR/STTR, DARPA, ARPA-E), R&D tax credits, revenue-based financing, customer prepayments, and convertible-free debt facilities. Venture debt is partially dilutive because of warrant coverage, but typically transfers under 1% of equity, so many founders include it in the broader non-dilutive category.
How much can a startup raise through SBIR/STTR?
Per SBA guidance updated October 2024, agencies may award Phase I up to $323,090 and Phase II up to $2,153,927 without seeking SBA approval. Across multiple awards from different federal agencies, a deep-tech company can pull several million dollars of equity-free capital before raising a Series A.
What is revenue-based financing?
A loan repaid as a percentage of monthly revenue until a multiple of the principal has been returned. Common in e-commerce and SaaS where revenue is predictable. No equity changes hands, no fixed monthly payment, and the lender's return scales with the company's growth.
When does non-dilutive funding make sense?
Whenever the cost of capital is lower than the implied cost of equity at the current valuation. Grants are free money for eligible projects. R&D tax credits reclaim cash already spent. Revenue-based financing makes sense when the alternative is selling equity at a price the founder believes will look low in hindsight.